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Abstract
Objective
To translate the quantitative MRC Centre MRI protocol in Charcot-Marie-Tooth disease type
1A (CMT1A) to a second site; validate its responsiveness in an independent cohort; and test
the beneﬁt of participant stratiﬁcation to increase outcome measure responsiveness.
Methods
Three healthy volunteers were scanned for intersite standardization. For the longitudinal
patient study, 11 patients with CMT1A were recruited with 10 patients rescanned at a 12-
month interval. Three-point Dixon MRI of leg muscles was performed to generate fat fraction
(FF) maps, transferred to a central site for quality control and analysis. Clinical data collected
included CMT Neuropathy Score.
Results
Test-retest reliability of FF within individual healthy calf muscles at the remote site was
excellent: intraclass correlation coeﬃcient 0.79, limits of agreement −0.67 to +0.85 %FF. In
patients, mean calf muscle FF was 21.0% and correlated strongly with disease severity and age.
Calf muscle FF signiﬁcantly increased over 12 months (+1.8 ± 1.7 %FF, p = 0.009). Patients
with baseline FF >10% showed a 12-month FF increase of 2.9% ± 1.3% (standardized response
mean = 2.19).
Conclusions
We have validated calf muscle FF as an outcome measure in an independent cohort of patients
with CMT1A. Responsiveness is signiﬁcantly improved by enrolling a stratiﬁed patient cohort
with baseline calf FF >10%.
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Charcot-Marie-Tooth disease (CMT) or hereditary motor
and sensory neuropathy is a common disease with a preva-
lence of 1 in 2,500. CMT causes progressive distal weakness,
sensory loss, and disability, with CMT type 1A (CMT1A)
accounting for more than half of all cases.1 There is currently
no disease-modifying therapy although a number of promis-
ing agents are in development. Trials of vitamin C were
negative2,3 but highlighted the need for responsive outcome
measures.
Quantitative skeletal muscle MRI has been widely studied as
an outcome measure in muscle diseases,4,5 and we recently
reported high responsiveness over 12 months in CMT1A in
a UK cohort.6 Intramuscular fat accumulation occurs as
a common feature of chronic pathology in muscle whether the
primary pathogenesis is neurogenic or myopathic, and can be
quantiﬁed with MRI using fat-water separation methods such
as the 3-point Dixon technique.5 In our previous study, this
provided the most responsive outcome measure with a 12-
month total calf muscle fat fraction (FF) increase of 1.2% ±
1.5% (p = 0.008) and standardized response mean (SRM) of
0.83, far exceeding that of any clinical outcome measure.6
However, it was recognized that this required further valida-
tion in an independent CMT1A cohort before application in
clinical trials.
We aimed to translate our MRC Centre MRI protocol to
a second site for validation in an independent patient co-
hort. We also tested the potential of stratiﬁcation based on
baseline muscle FF to increase outcome measure
responsiveness.
Methods
MRI was performed at the University of Iowa, Iowa City, with
anonymized MRI data transferred for analysis at the MRC
Centre for Neuromuscular Diseases, UCL Institute of Neu-
rology, London, UK.
Eleven patients with genetically conﬁrmed CMT1A were
recruited for examination at baseline and 12 months. Age,
disease duration, and the CMTNeuropathy Score (CMTNS)
(a composite disease severity scale ranging from 0 = normal to
36 = maximum severity) were recorded. For longitudinal
comparisons, the examination score (CMTES) component
was used. The Rasch-modiﬁed CMTNS and CMTES were
calculated.7
The MRC Centre MRI protocol, identical to that used
previously,4 was performed using a similar scanner (Siemens
3T TIM TRIO; Siemens Medical Solutions, Malvern, PA).
In brief, calf-level 3-point Dixon MRI was performed cen-
tered 130 mm distal from the knee joint.8 Muscle-group
cross-sectional regions of interest (ﬁgure 1) were drawn by
a single observer (J.M.M.) on the right calf muscle on the
central slice of the 3.45-millisecond Dixon acquisition to
allow extraction of the corresponding combined all-muscle-
group mean FF.
For remote-site quality-control qualiﬁcation, 3 healthy vol-
unteers were scanned with 2 undergoing repeat scanning on
a diﬀerent day to assess test-retest reliability, referenced to
similar measurements performed in London.9,10
Statistical analysis was performed using SPSS Statistics 20.0
(IBM Corp., Armonk, NY). Group data were compared using
Figure 1 Quantitative MRI in a range of disease severity in
Charcot-Marie-Tooth disease type 1A
Axial fat fraction map of the right calf 130 mm distal to the lateral tibial
plateau is shown on the left. Regions of interest (red: tibialis anterior/ex-
tensor hallucis longus; green: peroneus longus; purple: tibialis posterior;
light blue: soleus; dark blue: lateral gastrocnemius; yellow: medial gastroc-
nemius) and respective mean fat fraction values are overlaid on the right. In
the top patient, there is a slight increase in fat fraction in peroneus longus
only. In the middle row, marked involvement is seen with endstage in-
volvement of peroneus longus and both heads of the gastrocnemius. In the
bottom row, there is severe involvement of all muscle groups. CMTNS =
Charcot-Marie-Tooth Neuropathy Score.
Glossary
CMT = Charcot-Marie-Tooth disease; CMT1A = Charcot-Marie-Tooth disease type 1A; CMTES = Charcot-Marie-Tooth
examination score;CMTNS = Charcot-Marie-Tooth Neuropathy Score; FF = fat fraction; SRM = standardized response mean.
2 Neurology | Volume , Number  | Month 0, 2018 Neurology.org/N
student 2-tailed t tests, longitudinal change was assessed using
paired t test, andMRI-clinical associations were assessed using
Spearman rank correlation. Outcomemeasure responsiveness
was assessed using the SRM (mean change divided by the
change SD).
To investigate stratiﬁcation, the remote-site data were com-
bined with that from our previous study4 in a clinically similar
CMT1A patient group (20 patients with CMT1A, 11 men,
mean age 42.8 years, mean CMTES 8.0). Twelve-month FF
changes and SRMs were calculated for patients with baseline
overall muscle FFs above and below a threshold of 10%, for
both sites separately and combined.
Data availability
Anonymized data will be shared by request from any qualiﬁed
investigator.
Standard protocol approvals, registrations,
and patient consents
Both sites’ ethical review boards approved the study and all
participants gave written informed consent.
Results
Of the 11 patients with CMT1A assessed at baseline (6
women, 5 men, mean age 41, range 24–64 years; mean
baseline CMTNS 15.2, SD 5.9, range 5–23), 10 underwent
repeat assessment at median interval 1.03 years.
The remote-site qualiﬁcation FF measurements showed ex-
cellent test-retest reliability (intraclass correlation coeﬃcient
0.79; Bland-Altman limits of agreement −0.67 to +0.85 %FF).
No images were aﬀected by artifact, and repeat-scanning
block positions were suﬃciently consistent that the same
numerical slice could be used for follow-up analysis in all
cases.
Figure 1 shows FF in participants with mild, moderate, and
severe CMTNS. The patients’ baseline mean overall calf
muscle FF was 21% (median 8.7, interquartile range
5.2–34.1). Peroneus longus had the highest mean FF (37.9%),
with tibialis posterior the lowest (15.0%). Overall calf muscle
FF correlated strongly with age (ρ = 0.71, p = 0.01), CMTNS
(ρ = 0.695, p = 0.03), and Rasch-modiﬁed CMTNS (ρ = 0.81,
p = 0.004).
Overall calf muscle FF increased over 12 months (+1.8 ± 1.7
%FF, p = 0.009), with increases in peroneus longus and lateral
gastrocnemius also signiﬁcant (table). Calf muscle FF showed
high responsiveness (SRM 1.04), which improved on strati-
ﬁcation: patients with baseline FF >10% showed a 12-month
increase of 2.9 ± 1.3 %FF (SRM = 2.19) (table, ﬁgure 2).
Compared with the subgroup with <10% calf muscle FF,
those with FF >10% were older and more severely aﬀected
(mean age 50 years vs 34 years; mean Rasch-modiﬁed
CMTES 18 vs 7). The Rasch-modiﬁed CMTES increased
over 12 months but this was not statistically signiﬁcant (+1.4
± 2.6, p = 0.13).
Discussion
In this study, we successfully translated our calf-muscle MRC
Centre MRI protocol to an international remote site, and
further validated the value of calf-level muscle fat-fraction
measurement in an independent cohort of CMT1A patients
with high reliability, strong baseline cross-sectional clinical
correlations, and high responsiveness. Stratiﬁcation of the
cohort based on baseline FF further improved the SRM to
2.44 in the combined cohort, resulting in an estimated sample
size by the Lehr formula8 of 11 in each study arm of a ran-
domized controlled trial with 0.8 power to detect a 50%
slowing of disease progression at p < 0.05.
These data from an American cohort validate the results
obtained in our original British CMT1A cohort4 (ﬁgure 2)
and demonstrate international multisite trial readiness of
quantitative lower limb MRI in patients with CMT1A.
Table Longitudinal change in calf-level muscle FF by
muscle and stratified by baseline FF
Analysis subset
Mean FF
change
over 1 y, % SD, % p SRM
US cohort (n = 10) by
muscle
Tibialis anterior 0.8 1.9 0.19 0.45
Peroneus longus 1.6 2.1 0.04 0.74
Lateral gastrocnemius 3.7 3.1 0.005 1.19
Medial gastrocnemius 3.0 4.8 0.08 0.63
Soleus 1.7 2.6 0.07 0.65
Tibialis posterior 0.9 2.4 0.25 0.39
Overall 1.8 1.7 0.009 1.04
Restricted to patients
with baseline FF <10%
UK cohort (n = 12) 0.6 1.2 0.09 0.53
US cohort (n = 5) 0.6 1.3 0.32 0.51
UK + US combined
(n = 17)
0.6 1.2 0.04 0.54
Restricted to patients
with baseline FF >10%
UK cohort (n = 5) 2.7 1.1 0.005 2.49
US cohort (n = 5) 2.9 1.3 0.008 2.19
UK + US combined
(n = 10)
2.8 1.1 <0.001 2.44
Abbreviations: FF = fat fraction; SRM = standardized response mean.
p: Significance 2-tailed t test.
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Utilization of a positioning protocol based on a ﬁxed distance
from the knee joint6 resulted in improved block positioning
(10/10 scans within 1 cm of baseline in z-axis US vs 17/57
UK), conﬁrming the superiority of this method. The 3-point
Dixon method is robust after a brief study setup phase with no
regions of interest excluded from analysis because of artifact in
this study. The study setup phase was possible without an in-
person site visit with images transferred internationally for
quality-control purposes.
Outcome measure criterion validity was demonstrated with
both cohorts showing similar FF correlations with disease
severity (ρ = 0.81, p = 0.004 US with Rash-CMTS; ρ = 0.63, p
= 0.003 UK with CMTES) and age (ρ = 0.84, p < 0.001 UK; ρ
= 0.71, p = 0.01 US). Of note, the primary calf muscle FF
outcome measure proposed previously6 showed similar
increases (+1.2 ± 1.5 %FF UK, +1.8 ± 1.7 %FF US).
The SRM can be improved by participant stratiﬁcation (ﬁgure
2): including only patients with baseline calf muscle FF >10%
yielded an SRM >2 consistently in the United States, United
Kingdom, and combined cohorts (table), markedly higher
than the nonstratiﬁed groups. The inverse square relationship
of SRM to sample size implies a potential dramatic reduction
resulting in patient numbers needed in an equivalently pow-
ered study from 83 to 11 in each arm. Researchers would need
to consider a potential ceiling eﬀect in the trial design as the
calf muscle FF approached the maximum level with 78% the
highest value obtained across the 2 studies. There was less
responsiveness in those with low baseline FF at calf level.
Further studies to examine responsiveness of FF assessed in
the distal calf or foot musculature are in process to identify
a more responsive biomarker in this younger, more mildly
aﬀected subgroup. However, MRI calf muscle FF provides
a highly responsive outcome measure in an unselected adult
CMT population.
We have conﬁrmed the reliability, validity, and responsiveness
of theMRCCentreMRI quantiﬁed calf muscle FF protocol as
an outcome measure in an independent cohort of patients
with CMT1A. Selection of study participants with increased
baseline calf muscle FF provides a highly responsive bio-
marker in this patient group, suitable for utilization in multi-
center international clinical trials.
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